Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

JAMES THOMAS BARKER

Allopathic & Osteopathic Physicians Psychiatry & Neurology Psychiatry

NPI
1922189927
CMS profile
223531
Location
HICKORY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2019 · Entire year

$273,662.75

413 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2019 · entire year · sorted by reported total

By paying entity

PY2019 · entire year · sorted by reported total

Page 8 of 9; records 351–400 of 413 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

JAMES THOMAS BARKER

NPI 1922189927 · CMS profile ID 223531

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Psychiatry

HICKORY, NC

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 8 of 9; records 351–400 of 413 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1922189927?year=2019&recipient=provider&page=8#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
JAMES THOMAS BARKER, NPI 1922189927, CMS profile ID 223531. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 413 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1922189927?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
APA 7
IndustryPayments. (2026). JAMES THOMAS BARKER, NPI 1922189927, CMS profile ID 223531. General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 8 of 9; records 351–400 of 413 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1922189927?year=2019&recipient=provider&page=8#records-h. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e.
Bluebook
JAMES THOMAS BARKER, NPI 1922189927, CMS profile ID 223531, IndustryPayments, General Payments, PY2019; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 8 of 9; records 351–400 of 413 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/4e54dd6c-30f8-4f86-86a7-3c109a89528e. https://industrypayments.org/provider/npi-1922189927?year=2019&recipient=provider&page=8#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2019

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2019 · Physicians and non-physician practitioners · CMS publication 2026-06-30

413 matching records · $273,662.75 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 413 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 351–400 of 413.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Janssen Pharmaceuticals, Inc $3,080.0003/18/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296233 CMS
Janssen Pharmaceuticals, Inc $80.0403/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296237 CMS
Janssen Pharmaceuticals, Inc $194.6003/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296241 CMS
Janssen Pharmaceuticals, Inc $389.6703/18/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296245 CMS
Janssen Pharmaceuticals, Inc $33.8803/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296247 CMS
Janssen Pharmaceuticals, Inc $74.8703/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296251 CMS
Alkermes, Inc. $3,400.0003/15/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573437 CMS
Janssen Pharmaceuticals, Inc $1,540.0003/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296227 CMS
Janssen Pharmaceuticals, Inc $3,080.0003/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296229 CMS
Janssen Pharmaceuticals, Inc $14.4703/11/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296217 CMS
Alkermes, Inc. $900.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573407 CMS
Alkermes, Inc. $153.7003/08/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573429 CMS
Alkermes, Inc. $1,800.0003/08/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573431 CMS
Alkermes, Inc. $39.0903/08/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573617 CMS
Alkermes, Inc. $12.8703/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573561 CMS
Alkermes, Inc. $3.9503/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573563 CMS
Alkermes, Inc. $115.9303/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573603 CMS
Takeda Pharmaceuticals U.S.A., Inc. $15.1303/04/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 681779945 CMS
Alkermes, Inc. $3,400.0003/01/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573635 CMS
Alkermes, Inc. $151.3802/28/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573415 CMS
Janssen Pharmaceuticals, Inc $113.2802/28/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296213 CMS
Janssen Pharmaceuticals, Inc $119.3102/27/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296209 CMS
Alkermes, Inc. $2,800.0002/25/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573411 CMS
Alkermes, Inc. $21.2702/25/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573605 CMS
Alkermes, Inc. $258.4902/21/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573427 CMS
Alkermes, Inc. $100.0002/21/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573607 CMS
Alkermes, Inc. $207.4602/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573413 CMS
Alkermes, Inc. $90.8402/20/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573567 CMS
Alkermes, Inc. $4.6402/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573643 CMS
Janssen Pharmaceuticals, Inc $48.7202/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296198 CMS
Janssen Pharmaceuticals, Inc $42.9202/20/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296201 CMS
Alkermes, Inc. $58.0002/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573405 CMS
Alkermes, Inc. $92.8002/19/2019 Travel and Lodging No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573423 CMS
Bausch Health US, LLC $16.2702/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684519467 CMS
Bausch Health US, LLC $22.4602/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684519469 CMS
Lundbeck LLC $21.4002/19/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684281359 CMS
Neurocrine Biosciences, Inc. $15.2102/18/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 693113921 CMS
Alkermes, Inc. $18.2902/14/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573555 CMS
Janssen Pharmaceuticals, Inc $1,540.0002/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296171 CMS
Janssen Pharmaceuticals, Inc $3,080.0002/13/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296175 CMS
Alkermes, Inc. $125.0002/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573557 CMS
Sunovion Pharmaceuticals Inc. $21.7102/12/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687949669 CMS
Alkermes, Inc. $2,800.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573409 CMS
Alkermes, Inc. $2,800.0002/11/2019 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573441 CMS
Janssen Pharmaceuticals, Inc $87.3102/07/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296163 CMS
Lundbeck LLC $18.2902/06/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 684281357 CMS
Alkermes, Inc. $45.8502/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 686573553 CMS
Allergan Inc. $20.1102/05/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 670084503 CMS
Sunovion Pharmaceuticals Inc. $17.1101/30/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 687949667 CMS
Janssen Pharmaceuticals, Inc $12.6301/29/2019 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 658296149 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $273,662.75 413
PY2020 $132,743.63 292
PY2021 $189,724.83 380
PY2022 $235,421.10 406
PY2023 $372,558.11 551
PY2024 $428,197.30 558
PY2025 $508,882.98 641

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $222,836.02 35
PY2024 Principal investigator $320,460.13 54
PY2023 Principal investigator $223,098.18 100
PY2022 Principal investigator $1,056.14 5
PY2021 Principal investigator $73,188.50 11
PY2020 Principal investigator $437,398.88 48
PY2019 Principal investigator $666,716.12 65

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

35 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 Janssen Research & Development, LLC $380.00 12/29/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175415595
Principal investigator 1 Axsome Therapeutics, Inc. $3,764.23 12/11/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917106
Principal investigator 1 Axsome Therapeutics, Inc. $531.34 12/11/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917108
Principal investigator 1 Janssen Research & Development, LLC $140.00 12/11/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175415569
Principal investigator 1 Janssen Research & Development, LLC $262.00 12/04/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175415517
Principal investigator 1 Axsome Therapeutics, Inc. $5,666.98 11/14/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917104
Principal investigator 1 Axsome Therapeutics, Inc. $5,254.25 10/17/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917100
Principal investigator 1 Axsome Therapeutics, Inc. $531.34 10/17/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917102
Principal investigator 1 Sumitomo Pharma America, Inc. $900.00 10/09/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176650799
Principal investigator 1 Sumitomo Pharma America, Inc. $2,750.00 10/09/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176650803
Principal investigator 1 Sumitomo Pharma America, Inc. $1,290.00 10/09/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
AN 8-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS No dispute reported 06/30/2026 1176650840
Principal investigator 1 Janssen Research & Development, LLC $9,907.00 10/03/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Disorder with Insomnia Symptoms No dispute reported 06/30/2026 1175415601
Principal investigator 1 Axsome Therapeutics, Inc. $4,779.73 09/15/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917098
Principal investigator 1 Sumitomo Pharma America, Inc. $3,025.00 09/11/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176647459
Principal investigator 1 Axsome Therapeutics, Inc. $6,089.97 08/13/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917096
Principal investigator 1 Janssen Research & Development, LLC $22,500.00 07/31/2025 Non-covered Recipient Entity
IM SUPER HOLDINGS LLC
A Two-Part Multicenter, Double-Blind, Randomized Placebo-Controlled Study to Evaluate Efficacy and Safety and the Maintenance of Effect of 20-mg Seltorexant as Adjunctive Therapy to Antidepressants in Adult and Elderly Patients with Major Depressive Diso No dispute reported 06/30/2026 1175415524
Principal investigator 1 Axsome Therapeutics, Inc. $500.00 07/23/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917092
Principal investigator 1 Axsome Therapeutics, Inc. $5,453.04 07/23/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917094
Principal investigator 1 Axsome Therapeutics, Inc. $6,543.61 06/13/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917088
Principal investigator 1 Axsome Therapeutics, Inc. $31.34 06/13/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917090
Principal investigator 1 Axsome Therapeutics, Inc. $9,046.37 05/16/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917084
Principal investigator 1 Axsome Therapeutics, Inc. $554.00 05/16/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917086
Principal investigator 1 Axsome Therapeutics, Inc. $108.00 04/16/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917082
Principal investigator 1 Sumitomo Pharma America, Inc. $40.28 04/11/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176633437
Principal investigator 1 Axsome Therapeutics, Inc. $500.00 03/24/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917080
Principal investigator 1 Sumitomo Pharma America, Inc. $1,973.72 03/21/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176630769
Principal investigator 1 Sumitomo Pharma America, Inc. $148.98 03/03/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176629950
Principal investigator 1 Axsome Therapeutics, Inc. $2,048.36 02/18/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917078
Principal investigator 1 Axsome Therapeutics, Inc. $500.00 02/14/2025 Non-covered Recipient Entity
IMA Clinical Research, Hickory, North Carolina
A Randomized, Double-blind, Active-controlled Study of AXS-05 for the Prevention of Relapse of Depressive Symptoms No dispute reported 06/30/2026 1199917076
Principal investigator 1 Sumitomo Pharma America, Inc. $1,290.00 01/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624728
Principal investigator 1 Sumitomo Pharma America, Inc. $8,500.00 01/28/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624768
Principal investigator 1 Sumitomo Pharma America, Inc. $650.00 01/22/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624461
Principal investigator 1 Sumitomo Pharma America, Inc. $3,500.00 01/22/2025 Non-covered Recipient Entity
IMA EVALUATIONS LLC
A 24-WEEK, OPEN-LABEL STUDY EVALUATING THE EFFECTIVENESS, SAFETY AND TOLERABILITY OF SEP-363856 IN SUBJECTS WITH SCHIZOPHRENIA SWITCHED FROM TYPICAL OR ATYPICAL ANTIPSYCHOTIC AGENTS OLE. No dispute reported 06/30/2026 1176624475
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $67,005.93 01/15/2025 Non-covered Recipient Entity
The Ima Group
An Extension Study to Assess Long-Term Safety and Tolerability of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia No dispute reported 06/30/2026 1235993155
Principal investigator 1 E.R. Squibb & Sons, L.L.C. $46,670.55 01/06/2025 Non-covered Recipient Entity
The Ima Group
A Study to Assess Efficacy and Safety of Adjunctive KarXT in Subjects With Inadequately Controlled Symptoms of Schizophrenia (ARISE) No dispute reported 06/30/2026 1235993153